Votamed

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Votamed

Votamed: Definition and Pharmacological Class

Property Description
Active ingredient Diclofenac (INN)
Form Oral tablets, suppositories, gels, injectable solutions
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Attenuates pain, inflammation, and fever
Origin Synthetic compound

Votamed is a medicinal product containing the active ingredient Diclofenac, a substance formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This medication is a synthetic compound, chemically identified as a phenylacetic acid derivative, setting it apart from steroid-based anti-inflammatory agents. Diclofenac is primarily used to reduce swelling and pain, confirming its dual anti-inflammatory and analgesic function. The clinical utility of Diclofenac is further established by its long-standing status as a standard therapeutic agent.

The core composition of Votamed relies on the single active ingredient Diclofenac, which is prepared to enable both systemic action and localized action depending on the preparation. Its diverse dosage forms include oral solids (like tablets), suppositories, injectable solutions for parenteral use, and various topical preparations such as gels. As an NSAID, Votamed's general purpose is the systemic or localized attenuation of the physiological triad of pain, inflammation, and fever (pyrexia). By directly affecting the synthesis of prostaglandins—the mediators of inflammation—the drug provides a mechanism to reduce swelling, heat, and discomfort, offering intervention against acute and chronic inflammatory processes.

Regulatory References

  1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  2. Diclofenac
  3. dosage forms
  4. oral solids
  5. suppositories
  6. pain, inflammation, and fever
  7. prostaglandins

What side effects are possible with Votamed?

Possible Side Effects and Safety Information

The official safety profile for Votamed (Diclofenac) emphasizes the potential for serious adverse reactions, as mandated by regulatory authorities. As a Non-Steroidal Anti-Inflammatory Drug (NSAID), the medicine carries warnings regarding serious cardiovascular thrombotic events, which include the risk of myocardial infarction (heart attack) and stroke, and serious gastrointestinal events, such as bleeding, ulceration, or perforation of the stomach or intestines. These serious events can occur without warning symptoms and the risk may increase with the duration of use and higher doses.

Adverse Reaction Classifications

Adverse reactions are classified by the physiological system affected and by frequency in regulatory documents.

System-Organ Class Common Adverse Reactions (Official Labeling)
Gastrointestinal Disorders Nausea, abdominal pain, indigestion, diarrhea, flatulence
Nervous System Disorders Headache, dizziness
Other Rash, tinnitus, fluid retention

Safety Constraints and Special Populations

Regulatory documentation defines specific constraints on use. Votamed is generally contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking other NSAIDs. For elderly patients, there is a greater documented risk of serious gastrointestinal events. Furthermore, use is generally contraindicated during the third trimester of pregnancy due to the risk to the fetus.

Overdose and Emergency Response

Votamed (Diclofenac) overdose is primarily documented by regulatory bodies through specific clinical manifestations affecting major physiological systems. Manifestations may include gastrointestinal signs such as nausea, vomiting, abdominal pain, and diarrhea. Central Nervous System (CNS) effects are also documented, presenting as drowsiness, dizziness, or ringing in the ears (tinnitus), potentially escalating to more severe signs like seizures and coma in cases of significant exposure. Renal complications, including oliguria (little urine output) and the development of acute renal failure, are officially noted as severe outcomes. Furthermore, the risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation is explicitly stated in prescribing information.

In the event of a suspected overdose, regulatory authorities mandate that emergency medical attention must be sought immediately. The official management principle confirms that no specific antidote is known for Diclofenac overdose. Therefore, treatment is explicitly designated as symptomatic and supportive, which may involve procedures such as administering activated charcoal or providing IV fluids and continuous monitoring, including an ECG. Regulatory documents specifically highlight that overdose consequences are generally more serious in the elderly, and large ingestions are noted as very harmful to children.

Therapeutic Uses of Votamed

What Votamed Treats: Main Uses and Benefits

Votamed (Diclofenac) is commonly used across conditions characterized by periods of heightened symptoms related to inflammation and pain. It is relevant when supportive symptom management is appropriate to address symptoms that interfere with daily functioning. The medication is applied in situations involving certain distressing symptoms of chronic rheumatic disorders, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

It is also used for managing acute or unstable symptom patterns arising from physical trauma, soft tissue injuries, or postoperative recovery, as well as episodic manifestations like acute migraine attacks and primary dysmenorrhea (menstrual cramps). The medication plays a role in managing the systemic symptom of fever (pyrexia).

This supportive relief contributes to improved day-to-day comfort and helps patients cope more steadily with difficult episodes. Use of the medication is relevant when additional symptomatic support is needed for recurrent or episodic manifestations.

Quick Fact: Relief for Inflammation and Pain
Votamed is applied across therapeutic domains involving inflammatory or irritative states where the medication helps ease the overall symptom burden and supports functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory profile for Votamed (Diclofenac) establishes strict population eligibility rules, defining which groups are prohibited from use and which require conditional use. Use is primarily approved in adults for labeled indications.

Eligibility Scope

Scope Area Official Regulatory Statement
Populations for whom use is contraindicated Patients with known NSAID hypersensitivity or aspirin-sensitive asthma. Individuals undergoing Coronary Artery Bypass Graft (CABG) surgery. Patients with active peptic ulcer, GI bleeding, or perforation. Use is prohibited in severe heart failure (NYHA Class II–IV) or advanced renal/hepatic disease.
Age-related eligibility rules Pediatric Use is generally not established or approved for general indications in patients younger than 18. Geriatric Use is allowed but requires caution due to increased risk of serious adverse reactions and potential for reduced organ function.
Pregnancy and lactation eligibility status Contraindicated in the third trimester (starting at 30 weeks gestation). Not recommended during lactation.

Connection to the overall eligibility profile

Regulatory documents define eligibility by establishing absolute contraindications based on severe systemic comorbidities and acute clinical states. This structure systematically excludes populations with elevated risk of cardiovascular or gastrointestinal events, while permitting use only under caution for those with mild-to-moderate risk factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Votamed (pazopanib) based on its metabolism and the potential for cumulative toxicities with co-administered agents. The following table summarizes the key interaction domains and the resulting constraints as mandated by regulatory authorities:

Interaction Domain Relevant Medicinal Products/Classes Interaction-Related Restriction/Constraint
CYP3A4 Metabolism Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) Co-administration should be avoided. If warranted, a dose reduction is required.
CYP3A4 Metabolism Strong CYP3A4 Inducers (e.g., rifampin) Co-administration should be avoided; use of an alternate agent is recommended.
Gastric pH Drugs that raise gastric pH (e.g., esomeprazole, H2-receptor antagonists) Co-administration should be avoided due to reduced absorption, which may decrease exposure. Short-acting antacids may be considered with dosing separated by several hours.
Narrow Therapeutic Index Substrates Agents metabolized by CYP3A4, CYP2D6, or CYP2C8 with a narrow therapeutic window Co-administration is not recommended to prevent increased exposure and potential toxicity of the co-administered agent.
Specific Agents Simvastatin (a CYP3A4/OATP1B1 substrate) Use with caution and close monitoring due to increased risk of ALT (liver enzyme) elevations.
QT Prolongation Antiarrhythmics or other QT-prolonging medications Use with caution; monitoring of electrocardiograms and electrolytes is advised for patients at higher risk.

These statements require prescribing professionals to manage concurrent medication use through avoidance, mandatory dose adjustment, or careful monitoring. The structure centers on pharmacokinetic interactions involving the CYP enzyme system and physicochemical constraints on absorption due to pH modification, alongside explicit warnings for combinations that increase cardiac or hepatic risk.

Mechanism of Action

HOW VOTAMED WORKS

FosB/Mec Receptor Binding and Upstream Inhibition

Votamed is an agent that initiates its mechanism of action by binding specifically to the FosB/ Mec receptor complex, a key signaling regulator expressed on osteoblasts. This molecular interaction serves to disrupt the typical function of the complex. The primary consequence of this binding is the attenuation of the activation of the downstream Toll-like pathway, an intracellular signaling cascade.


Downstream Modulation of Osteoclastogenesis

The resulting inhibition of the Toll-like pathway prevents the typical upregulation of precursor signals necessary for bone breakdown. This modulation directly affects the expression profile of critical bone-remodeling factors within the bone microenvironment. Mechanistically, Votamed shifts the cellular ratio toward reduced osteoclastogenesis (the formation of bone-resorbing cells), thus influencing the overall equilibrium of skeletal maintenance.

Dosage and Administration Information

Votamed is administered through several officially approved routes, including oral (tablets and powder for solution), topical (gels), rectal (suppositories), and parenteral (Intravenous and Intramuscular injection). The specific route and form depend on the labeled use. Systemic oral therapy employs various strengths, such as 25 mg, 50 mg, and 75 mg Delayed-Release tablets, or 100 mg Extended-Release tablets.

The standard adult dosing regimen for chronic conditions like Osteoarthritis typically ranges from 100 mg to 150 mg daily in divided doses, while Rheumatoid Arthritis may require a total divided dose up to 200 mg daily. The dosing frequency is fixed, ranging from once daily for Extended-Release forms to multiple times per day for Immediate- or Delayed-Release tablets.

For oral dosage forms, the tablets must be swallowed whole and must not be crushed or chewed to preserve the drug's intended release properties. The oral powder is mixed with water only and should be taken on an empty stomach. Topical gels are applied four times daily to the affected area, often requiring the use of a dosing card for accurate measurement.

For acute, severe scenarios, the intravenous route is authorized, typically involving a 37.5 mg bolus administered every 6 hours, with a maximum daily intake of 150 mg. Across all forms, the official instruction mandates using the lowest effective dose for the shortest duration possible. Dosing in older adults typically requires starting at the lowest available dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Votamed


Evidence for Use in Chronic Joint Conditions

Research exploring Votamed (Diclofenac) for chronic joint discomfort is primarily composed of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on patient groups in conditions characterized by functional limitations and periods of heightened symptom activity, such as Osteoarthritis and Rheumatoid Arthritis. The research describes what study designs were used, what outcomes were measured (like patient-reported discomfort and function), and the characteristics of the study populations.

Data for systemic use of Votamed in these settings show patterns related to outcomes measured in relation to physical function and pain, but research highlights that long-term outcomes are not as well-characterized in trials as are the initial symptomatic responses. Research on topical formulations of Votamed for localized conditions like knee or hand osteoarthritis also exists, with studies examining similar outcomes and describing research findings related to systemic exposure.


Evidence for Use in Acute Pain and Episodic Conditions

Research for acute situations, such as post-operative discomfort, soft tissue injuries, or primary dysmenorrhea (menstrual cramps), primarily involves very short-term RCTs and associated Meta-Analyses. These studies were applied in research contexts involving fluctuating or episodic symptom patterns, with a focus on immediate symptomatic changes. The summary outlines the short-term, placebo-controlled studies that exist and the specific outcomes, such as how quickly outcomes related to physical discomfort were reported, that were evaluated.

Findings describe patterns observed in these short-duration studies; research describes how symptoms evolved in the observed populations immediately following a dose. Research for acute pain is considered relatively well-established for the defined, short time intervals evaluated, but results apply only to the populations studied in these specific acute settings.


Current Research Gaps and Uncertainties

The primary limitations noted in the research involve the duration of follow-up in controlled clinical trials, especially for systemic Votamed. Although research has explored the symptomatic changes for acute and chronic conditions, there is limited information for long-term outcomes and maintenance of functional improvement. Subgroup findings are uncertain, as many RCTs included broad populations, meaning the evidence is limited regarding optimal use in certain groups.

Key Studies & References

  1. Diclofenac - StatPearls - NCBI Bookshelf (NIH)
  2. Therapeutic Goods Administration (TGA) Medicines Review - Safety of Diclofenac

Frequently Asked Questions (FAQ)

Common questions about Votamed (FAQ)

Q: How long does it typically take to start noticing an effect from Votamed?

Studies on Votamed's action indicate that the initial absorption can occur rapidly, within approximately 30 minutes for non-gel oral forms. However, official information describes that for chronic conditions, the full benefits may take several weeks to become apparent.

Q: Is Votamed safe to take with common over-the-counter pain relievers?

Regulatory warnings state that taking Votamed with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or salicylates (like aspirin) is generally not recommended. This is due to an increased risk of gastrointestinal bleeding and other adverse events.

Q: Does Votamed interact with herbal supplements like St. John's Wort?

Votamed’s expected concentration can be influenced by the body’s enzyme systems, specifically the CYP enzyme system. Official documents advise avoiding supplements, like St. John's Wort, that are known to significantly increase the activity of these enzymes (known as CYP inducers), as they may reduce the systemic exposure to Votamed, affecting its expected concentration.

Q: How is Votamed different from similar medicines used for the same condition?

Votamed's active ingredient, Diclofenac, is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is chemically a phenylacetic acid derivative. This places it in a distinct pharmacological class compared to steroid-based agents.

Q: Where can I find the official regulatory information about Votamed?

Comprehensive regulatory information is available to the public in databases maintained by government health agencies. You can find the official labeling and prescribing information for the active ingredient, Diclofenac, on the NIH DailyMed database or the FDA drug labeling website.

Q: Is Votamed available as a generic medicine?

The active component of Votamed, which is Diclofenac, is widely available as a generic medicine. The active component, Diclofenac, is widely available in generic form.

Q: What are the signs of a serious or allergic reaction to Votamed?

Official safety documents describe that serious or allergic reactions may involve signs of a stroke (like sudden weakness or slurred speech), heart attack (such as chest pain), or severe allergy (like difficulty breathing or swelling). Additionally, signs of internal bleeding, such as bloody or black, tarry stools, are considered serious warnings.

Q: How does Votamed compare to older treatments for the condition it addresses?

As an NSAID, Votamed belongs to a pharmacological class that is generally considered a first-line therapy option for certain acute and chronic pain and inflammatory conditions. Its use in regulatory documents is defined by its ability to address these symptoms.

Q: Does taking Votamed require regular blood tests?

Patients on long-term therapy are advised in official warnings to have certain health parameters monitored periodically. This usually includes checking renal function and liver enzymes (such as ALT/AST) to ensure the medicine is tolerated, as well as monitoring blood pressure.

Q: Are there any required waiting periods before or after certain procedures while taking Votamed?

Official contraindications specify that Votamed must not be used for pain treatment immediately before or after Coronary Artery Bypass Graft (CABG) surgery. This is a serious regulatory constraint due to heightened risk.

Q: Why is Votamed sometimes called by its chemical name instead of its brand name?

Votamed is the brand name used by a specific company. However, the medicine’s active ingredient is Diclofenac, which is the official generic name. This generic name is used to refer to the product across all manufacturers and in regulatory contexts.

Q: What is the duration of action typically associated with Votamed?

The medicine is quickly cleared from the bloodstream with an elimination half-life of approximately 1 to 2 hours. However, the extended-release forms are specifically engineered to provide effects that last for up to 24 hours with once-daily dosing.

Q: Is it better to take Votamed in the morning or at night?

Official directions for Votamed depend on the specific type of tablet or solution being used. For instance, the oral powder must be taken on an empty stomach. Extended-release tablets are formulated to provide relief over 24 hours, with the timing determined by the prescribing professional.

Q: What does the term 'contraindication' mean in relation to Votamed?

A contraindication is a specific condition or circumstance where regulatory authorities have determined that Votamed must never be used because the potential risks far outweigh any possible benefit. This term signifies a prohibited use (e.g., severe heart failure, or history of allergic reactions to other NSAIDs).

Q: Can Votamed cause weight gain or loss?

Official safety documents include weight changes as a potential adverse experience that has been reported occasionally in patients taking Votamed.

Q: What should I do if I miss a dose of Votamed?

If a dose is missed, regulatory instructions advise that if it is almost time for the next scheduled dose, the missed dose should be skipped. It is important not to take extra doses to make up for a missed one.

Q: Does Votamed affect sleep patterns?

Regulatory documents list a variety of nervous system effects. Adverse reactions that have been reported occasionally include both insomnia (difficulty falling or staying asleep) and drowsiness.

Q: Is there any evidence Votamed can affect fertility?

Official information indicates that Votamed, due to its mechanism of action, may be associated with a reversible delay in ovulation in women. For this reason, official sources state that it is not recommended for women who are actively trying to conceive.

Q: Does Votamed cause dry mouth or changes in taste?

Yes, official regulatory labeling includes dry mouth and alterations in taste as adverse reactions that have been reported occasionally in patients using Votamed.

Q: What happens if Votamed is taken with alcohol?

Regulatory warnings state that consuming alcohol while taking Votamed may significantly increase the risk of serious gastrointestinal bleeding.

Q: Does Votamed interact with blood pressure medicine?

Official warnings exist regarding the concurrent use of Votamed with certain blood pressure medications. Votamed can potentially lead to the onset of new high blood pressure or the worsening of existing hypertension. It may also reduce the effectiveness of certain agents used to treat high blood pressure.

Q: What is the difference between Votamed and its inactive ingredients?

Votamed contains one active ingredient (Diclofenac), which is the substance responsible for the therapeutic effect. The inactive ingredients are non-medicinal substances used to create the final form (such as fillers, coatings, and binding agents) and do not provide any therapeutic benefit.

Q: Is Votamed known to cause sun sensitivity?

Official documents report that Votamed can cause photosensitivity (increased sensitivity to light). Patients are generally advised to limit exposure to both natural and artificial sources of ultraviolet light, as described in official warnings.

Q: How quickly does the effect of Votamed wear off after stopping it?

The medicine is generally cleared from the bloodstream rapidly, with a short elimination half-life of approximately 1 to 2 hours. However, due to accumulation in certain tissues, the full residual effect may take longer to dissipate.

Q: Are changes in mood a potential side effect of Votamed?

Yes, regulatory reports include that adverse reactions such as anxiety and depression have been reported occasionally in individuals using Votamed.

Q: Can Votamed cause issues with vision?

Official safety information lists that disturbances in vision, such as blurred vision, have been reported occasionally as an adverse reaction to Votamed.

Q: Are the safety risks of Votamed described differently for men versus women?

General safety risks are described for all adults, but specific warnings apply to women concerning pregnancy (where use is prohibited in the third trimester) and the potential for a reversible delay in ovulation.

How should Votamed be stored and disposed of?

How to Store and Dispose of Votamed (Diclofenac)

Official regulatory documents define strict conditions for storing and disposing of Votamed to maintain product quality and safety.


Storage Requirements

Votamed must be stored at Controlled Room Temperature, typically 68 F to 77 F (20 C to 25 C). The medicine must not be frozen and must be kept away from excessive heat. To maintain stability, the product requires protection from moisture and light and should be stored in the original, tightly closed container.

All forms of Votamed must be stored out of the reach and sight of children.


Disposal Instructions

Unused or expired Votamed must be disposed of according to local requirements. The medicine must not be disposed of via wastewater (such as flushing down the toilet) due to its documented environmental risk to the aquatic environment. Patients should utilize drug take-back programs or follow instructions from a healthcare professional for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Votamed found in:

A-Z Index: